Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

KY61559X1045
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00XQZQTS9
MLTX
MoonLake Immunotherapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
MoonLake Immunotherapeutics
ISIN
KY61559X1045
TICKER
MLTX
MIC
XNAS
REUTERS
MLTX.OQ
BLOOMBERG
MLTX US
Thu, 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 3, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHA...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.12.2025       Moonlake Immunotherapeutics
KY61559X1045

MLTX Investor with Losses Encourages to Contact Firm by Dec. 15 DeadlineSAN FRANCISCO, Dec. 3, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX)...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 2, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Moonlake Immunotherapeutics
KY61559X1045

BENSALEM, Pa., Dec. 2, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOONLAKE IMMUNOTHERAPEUTIC...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 1, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHA...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Lead Partner Reed Kathrein Investigating Alleged Undisclosed Truth: Did SLK's Nanobody Structure Truly Confer a Superior Clinical Benefit Over Monoclonal Antibodies?SAN FRANCISCO, Dec. 1, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 01.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 1, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX)....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encourag...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Moonlake Immunotherapeutics
KY61559X1045

PHILADELPHIA, Dec. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period")....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES  , Dec. 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 30.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 30.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 30.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WH...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.11.2025       Moonlake Immunotherapeutics
KY61559X1045

SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the release of disappointing Phase 3 trial results for its lead and...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 28.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 28, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 27, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.11.2025       Moonlake Immunotherapeutics
KY61559X1045

MLTX Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - November 27, 2025) - MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was tri...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 26, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       Moonlake Immunotherapeutics
KY61559X1045

SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the release of disappointing Phase 3 trial results for its lead and...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 26, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.11.2025       Moonlake Immunotherapeutics
KY61559X1045

MLTX Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, Nov. 25, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the r...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 24, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WH...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encoura...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       Moonlake Immunotherapeutics
KY61559X1045

PHILADELPHIA, Nov. 24, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period")....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 23.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 23, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 23.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 22.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 22.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 22.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 22, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.11.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Nov. 21, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) have opportunity to lead the securities fraud class action lawsuit....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 21, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholder...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 19, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 19, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=178166&wire=5&...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink